Slate Path Capital LP Arrowhead Pharmaceuticals, Inc. Transaction History
Slate Path Capital LP
- $5.05 Billion
- Q1 2025
A detailed history of Slate Path Capital LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Slate Path Capital LP holds 5,232,000 shares of ARWR stock, worth $81.7 Million. This represents 1.32% of its overall portfolio holdings.
Number of Shares
5,232,000
Previous 5,232,000
-0.0%
Holding current value
$81.7 Million
Previous $98.4 Million
32.23%
% of portfolio
1.32%
Previous 1.89%
Shares
4 transactions
Others Institutions Holding ARWR
# of Institutions
300Shares Held
98MCall Options Held
306KPut Options Held
432K-
Black Rock Inc. New York, NY15.7MShares$245 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$206 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$174 Million2.29% of portfolio
-
State Street Corp Boston, MA7MShares$109 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL4.79MShares$74.7 Million0.02% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $1.65B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...